A systematic review of the effectiveness, cost-effectiveness and barriers to implementation of thrombolytic and neuroprotective therapy for acute ischaemic stroke in the NHS - PubMed (original) (raw)
Review
doi: 10.3310/hta6260.
Affiliations
- PMID: 12433319
- DOI: 10.3310/hta6260
Free article
Review
A systematic review of the effectiveness, cost-effectiveness and barriers to implementation of thrombolytic and neuroprotective therapy for acute ischaemic stroke in the NHS
P Sandercock et al. Health Technol Assess. 2002.
Free article
No abstract available
Similar articles
- Cost-effectiveness of thrombolysis with recombinant tissue plasminogen activator for acute ischemic stroke assessed by a model based on UK NHS costs.
Sandercock P, Berge E, Dennis M, Forbes J, Hand P, Kwan J, Lewis S, Lindley R, Neilson A, Wardlaw J. Sandercock P, et al. Stroke. 2004 Jun;35(6):1490-7. doi: 10.1161/01.STR.0000126871.98801.6E. Epub 2004 Apr 22. Stroke. 2004. PMID: 15105519 - Thrombolytic therapy with alteplase for ischaemic stroke.
[No authors listed] [No authors listed] Drug Ther Bull. 2009 Feb;47(2):14-8. doi: 10.1136/dtb.2009.01.0001. Drug Ther Bull. 2009. PMID: 19193701 Review. - Cost-Effectiveness of Endovascular Stroke Therapy: A Patient Subgroup Analysis From a US Healthcare Perspective.
Kunz WG, Hunink MG, Sommer WH, Beyer SE, Meinel FG, Dorn F, Wirth S, Reiser MF, Ertl-Wagner B, Thierfelder KM. Kunz WG, et al. Stroke. 2016 Nov;47(11):2797-2804. doi: 10.1161/STROKEAHA.116.014147. Epub 2016 Oct 6. Stroke. 2016. PMID: 27758942 - Cost-effectiveness of endovascular therapy for acute ischemic stroke.
Chen M. Chen M. Neurology. 2012 Sep 25;79(13 Suppl 1):S16-21. doi: 10.1212/WNL.0b013e31826957df. Neurology. 2012. PMID: 23008392 Review. - Reimbursement for thrombectomy devices in patients who are ineligible for intravenous tissue-type plasminogen activator.
Broderick JP, Tomsick TA; Interventional Management of Stroke (IMS) III Executive Committee. Broderick JP, et al. Stroke. 2013 May;44(5):1215-6. doi: 10.1161/STROKEAHA.113.001442. Epub 2013 Apr 18. Stroke. 2013. PMID: 23598521 No abstract available.
Cited by
- Stroke: Stroke outcomes after 90 days—out of sight, out of mind?
MacLeod MJ, Turner M. MacLeod MJ, et al. Nat Rev Neurol. 2015 Apr;11(4):187-8. doi: 10.1038/nrneurol.2015.28. Epub 2015 Mar 10. Nat Rev Neurol. 2015. PMID: 25752949 No abstract available. - Clarification of terminology in drug safety.
Aronson JK, Ferner RE. Aronson JK, et al. Drug Saf. 2005;28(10):851-70. doi: 10.2165/00002018-200528100-00003. Drug Saf. 2005. PMID: 16180936 Review. - National use of thrombolysis with alteplase for acute ischaemic stroke via telemedicine in Denmark: a model of budgetary impact and cost effectiveness.
Ehlers L, Müskens WM, Jensen LG, Kjølby M, Andersen G. Ehlers L, et al. CNS Drugs. 2008;22(1):73-81. doi: 10.2165/00023210-200822010-00006. CNS Drugs. 2008. PMID: 18072816 - Modeling stroke management: a qualitative review of cost-effectiveness analyses.
Guilhaume C, Saragoussi D, Cochran J, François C, Toumi M. Guilhaume C, et al. Eur J Health Econ. 2010 Aug;11(4):419-26. doi: 10.1007/s10198-010-0228-4. Epub 2010 Mar 18. Eur J Health Econ. 2010. PMID: 20238137 Review. - Thrombolysis for acute ischaemic stroke.
Wardlaw JM, Murray V, Berge E, del Zoppo GJ. Wardlaw JM, et al. Cochrane Database Syst Rev. 2014 Jul 29;2014(7):CD000213. doi: 10.1002/14651858.CD000213.pub3. Cochrane Database Syst Rev. 2014. PMID: 25072528 Free PMC article. Review.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical